Andrew Tsai
Stock Analyst at Jefferies
(3.20)
# 1,180
Out of 5,162 analysts
28
Total ratings
50%
Success rate
3.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $156.08 | +56.97% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $18.06 | +66.11% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.61 | +48.20% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $52.56 | -42.92% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $293.95 | +53.09% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $19.07 | +67.80% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $22.26 | +12.31% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $181.55 | +4.65% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $16.40 | +113.41% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $33.19 | -9.61% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $69.41 | +0.85% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $4.73 | -47.15% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $16.73 | +61.39% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $5.91 | +119.97% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $27.84 | +25.72% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.69 | +77.51% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.69 | +631.71% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $55.23 | -58.36% | 1 | Jun 1, 2020 |
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $156.08
Upside: +56.97%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $18.06
Upside: +66.11%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.61
Upside: +48.20%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $52.56
Upside: -42.92%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $293.95
Upside: +53.09%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $19.07
Upside: +67.80%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $22.26
Upside: +12.31%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $181.55
Upside: +4.65%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $16.40
Upside: +113.41%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $33.19
Upside: -9.61%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $69.41
Upside: +0.85%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $4.73
Upside: -47.15%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $16.73
Upside: +61.39%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $5.91
Upside: +119.97%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $27.84
Upside: +25.72%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.69
Upside: +77.51%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.69
Upside: +631.71%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $55.23
Upside: -58.36%